ArticlePain reports2026
A real-world database analysis of the prevalence of pain medication use in the United States.
Article in Pain reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pain is a common and burdensome condition associated with significant health care costs and patient morbidity in the United States, yet limited pain prevalence data exists. Objectives: Provide national-level prevalence estimates of acute and chronic pain requiring management with prescription medication in the United States. Examine medication treatment patterns for the overall pain populations and a subset of patients with peripheral neuropathic pain (PNP). Methods: This study used a retrospective cross-sectional design that identified adults receiving treatment for pain in 2022 in the MarketScan Commercial and Medicare Supplemental and the Premier Healthcare Databases. Pain prevalence and medication use were analyzed and extrapolated to the United States population using standardized prevalence estimation methods. Results: Results suggest that approximately 102.1 million (M) people in the United States received prescription pain medication in 2022. Approximately 28.7M people received prescription medications for chronic pain, of which 11.1M (39%) had PNP conditions. Most patients with chronic pain used prescription nonsteroidal anti-inflammatory drugs (NSAIDs; 51%), anticonvulsants (44%), opioids (41%), and antidepressants (40%). Anticonvulsant use was more prominent in PNP (62% of patients had ≥1 prescription). Acute pain was estimated to affect 80.2M adults in the United States; 46.2M people with pain medication administered in-hospital, 43.5M filling prescription pain medications and 9.4M in both settings. Among all acute pain patients, 48% and 42% had evidence of opioid and NSAID use, respectively. Approximately 6.8M patients with chronic pain also experienced an acute pain event in-hospital. Conclusion: Findings show pain, pain medication use, and opioid-use in particular, are highly prevalent in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.